Terms ending in 2027
Every in-force patent on NuVasive, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,653,894 | System and Methods for Nerve Monitoring In force · Medium confidence | NuVasive, Inc. | In force | Medium confidence | |
| US D674,092 | Intervertebral Implant In force · Medium confidence | NuVasive, Inc. | In force | Medium confidence | |
| US 8,827,900 | Surgical Access System and Related Methods In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US 8,480,712 | System and Method for Performing Spinal Fixation In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US 8,147,521 | Systems and Methods for Treating Spinal Deformities In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US D675,320 | Intervertebral Implant In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US D721,808 | Intervertebral Implant In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US 7,887,595 | Methods and Apparatus for Spinal Fusion In force · High confidence | NuVasive, Inc. | In force | High confidence | |
| US 10,507,265 | Cancellous Bone Product Including Viable Osteogenic Cells In force · Medium confidence | NuVasive, Inc. | In force | Medium confidence | |
| US 11,471,560 | Cancellous Bone Product Including Viable Osteogenic Cells In force · Medium confidence | NuVasive, Inc. | In force | Medium confidence | |
| 18 more term ends in 2027 · Pro | |||||
10 of 28 patents shown. Soonest term end first, then patent number.
Pro members see all 28, all of them expiring within the 18 months from Nov 18, 2026.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.